Early detection supports more informed referrals
14-3-3η is clinically proven biomarker which predicts Rheumatoid Arthritis (RA) development in patients with joint pain and helps assists with early diagnosis. The 14-3-3η blood test can identify RA earlier than traditional blood tests alone, identifying 21% of early RA patients and 67% of established RA patients who test negative in RF and anti-CCP blood tests.
Labcorp Panels:
These panels are designed to stratify patients for risk of joint destruction and/or radiographic progression, and to monitor disease activity and effectiveness of treatment.
RheumAssure®
The RheumAssure® test panel includes Anti-CCP 3.1, Rheumatoid Factor (RF) and 14-3-3η for high sensitivity for both early (78-92%) and established (88-96%) RA to support accurate diagnosis.
RheumAssure®
HCP Ordering Information
Test code: 504509
Sample Report
RAdx6 Profile
The RAdx6 test panel includes RF by Turb; Anti-CCP (Cyclic Citrullinated Peptide) Ab, IgG & IgA; 14.3.3 eta; Anti-CEP1 Ab, IgG; Anti-Sa Ab; Anti-CEP1 (citrullinated alpha-enolase 1) Ab; Anti-Sa (citrullinated vimentin) Ab; Anti-CarP (carbamylated protein) Ab.